Verici Dx plc (LON:VRCI – Get Free Report)’s share price traded down 11.1% during trading on Thursday . The company traded as low as GBX 6 ($0.08) and last traded at GBX 6 ($0.08). 109,832 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 318,065 shares. The stock had previously closed at GBX 6.75 ($0.09).
Verici Dx Stock Performance
The stock has a fifty day moving average of GBX 6.90 and a 200-day moving average of GBX 7.37. The company has a quick ratio of 8.49, a current ratio of 4.54 and a debt-to-equity ratio of 4.65. The stock has a market cap of £15.64 million, a PE ratio of -322.50 and a beta of 1.59.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Recommended Stories
- Five stocks we like better than Verici Dx
- Why Invest in High-Yield Dividend Stocks?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Best Stocks Under $5.00
- MarketBeat Week in Review – 9/30 – 10/4
- ETF Screener: Uses and Step-by-Step Guide
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
